Yatharth Hospital & Trauma Care Services Ltd: Valuation Shifts Signal Renewed Price Attractiveness

Valuation Metrics: From Expensive to Fair

As of early March 2026, Yatharth Hospital & Trauma Care Services Ltd trades at a P/E ratio of 38.23 and a P/BV of 3.79. These figures represent a marked improvement in valuation attractiveness compared to previous levels when the stock was considered expensive. The company’s enterprise value to EBITDA (EV/EBITDA) stands at 23.62, while the EV to EBIT ratio is 32.43, both indicating a more reasonable pricing relative to earnings before interest, taxes, depreciation, and amortisation.

In contrast, several peers in the hospital sector continue to command significantly higher valuations. For instance, Aster DM Healthcare and Krishna Institute of Medical Sciences are trading at P/E ratios of 89.79 and 96.74 respectively, both classified as expensive. Similarly, Dr Lal Pathlabs and Dr Agarwal’s Healthcare maintain very expensive valuations with P/E ratios exceeding 40 and 100 respectively. This comparative context highlights Yatharth Hospital’s relative value proposition, especially for investors seeking exposure to the hospital sector without the premium multiples.

Mojo Grade Downgrade and Market Sentiment

Despite the improved valuation metrics, Yatharth Hospital’s overall Mojo Grade was downgraded from Hold to Sell on 6 February 2026, with a current Mojo Score of 45.0. This downgrade reflects concerns beyond valuation, including operational challenges or growth prospects that may have influenced analyst sentiment. The company’s market capitalisation grade remains modest at 3, indicating a small-cap status that may contribute to higher volatility and risk perception among investors.

On the trading front, the stock has experienced a day change of -2.21%, closing at ₹664.05 against a previous close of ₹679.05. The 52-week price range spans from ₹345.35 to ₹843.00, underscoring significant price fluctuations over the past year. Notably, the stock has delivered a robust one-year return of 81.71%, substantially outperforming the Sensex’s 8.39% gain over the same period. However, shorter-term returns have been mixed, with a one-week decline of 4.75% contrasting with a one-month gain of 6.27%.

Return on Capital and Equity: Assessing Operational Efficiency

Yatharth Hospital’s latest reported return on capital employed (ROCE) stands at 12.32%, while return on equity (ROE) is 9.03%. These figures suggest moderate operational efficiency and profitability, though they lag behind some larger peers in the hospital sector. For example, companies with very expensive valuations often justify their premium multiples through superior returns and growth prospects. The current ROCE and ROE levels indicate that while Yatharth Hospital is generating reasonable returns, there remains scope for improvement to enhance investor confidence and justify higher valuations.

Comparative Valuation and Sector Context

Within the hospital sector, valuation multiples vary widely, reflecting differences in scale, growth trajectory, and market positioning. Yatharth Hospital’s P/E of 38.23 and EV/EBITDA of 23.62 place it comfortably below the sector’s expensive and very expensive peers, signalling a more accessible entry point for value-conscious investors. The PEG ratio of 1.34 further supports a balanced valuation relative to expected earnings growth, contrasting with some peers where PEG data is unavailable or indicates overvaluation.

Interestingly, Health.Global is classified as attractive despite a very high P/E of 264.42, likely due to exceptional growth expectations or other qualitative factors. Meanwhile, other fair-valued companies such as Jupiter Life Line and Park Medi World trade at P/E ratios of 43.96 and 39.39 respectively, close to Yatharth Hospital’s current multiples. This cluster of fair valuations suggests a segment of the hospital sector where investors can find reasonable pricing without sacrificing growth potential.

Price Movement and Market Volatility

The stock’s recent price action reflects a degree of volatility, with intraday trading ranging between ₹658.00 and ₹688.00 on the latest session. The 52-week high of ₹843.00 and low of ₹345.35 illustrate a wide trading band, indicative of market uncertainty or episodic news flow impacting investor sentiment. The one-year return of 81.71% is a standout performance relative to the Sensex’s 8.39%, highlighting the stock’s capacity for strong gains despite short-term fluctuations.

Investment Implications and Outlook

The shift in valuation grade from expensive to fair for Yatharth Hospital & Trauma Care Services Ltd presents a nuanced opportunity for investors. While the downgrade in Mojo Grade to Sell signals caution, the more reasonable multiples relative to peers and historical levels may attract value-oriented buyers seeking exposure to the hospital sector’s growth potential at a moderated price.

Investors should weigh the company’s operational metrics, including ROCE and ROE, alongside market volatility and sector dynamics. The hospital industry remains competitive, with larger players commanding premium valuations justified by scale and profitability. Yatharth Hospital’s smaller market capitalisation and recent price correction could offer a tactical entry point, provided investors are comfortable with the associated risks and the company’s growth trajectory.

In summary, the recent valuation adjustment enhances Yatharth Hospital’s price attractiveness, but the overall investment case requires careful analysis of fundamentals and market conditions. Monitoring future earnings reports, sector trends, and peer performance will be crucial to realising the stock’s potential in the evolving healthcare landscape.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today